Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding
Others
Ratios

Viking Therapeutics (VKTX) Operating Income (2016 - 2025)

Historic Operating Income for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to -$164.7 million.

  • Viking Therapeutics' Operating Income fell 25628.27% to -$164.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$393.3 million, marking a year-over-year decrease of 16062.77%. This contributed to the annual value of -$393.3 million for FY2025, which is 16062.77% down from last year.
  • According to the latest figures from Q4 2025, Viking Therapeutics' Operating Income is -$164.7 million, which was down 25628.27% from -$98.6 million recorded in Q3 2025.
  • Over the past 5 years, Viking Therapeutics' Operating Income peaked at -$12.5 million during Q4 2021, and registered a low of -$164.7 million during Q4 2025.
  • For the 5-year period, Viking Therapeutics' Operating Income averaged around -$38.6 million, with its median value being -$25.5 million (2023).
  • In the last 5 years, Viking Therapeutics' Operating Income crashed by 1104.21% in 2021 and then plummeted by 25628.27% in 2025.
  • Quarter analysis of 5 years shows Viking Therapeutics' Operating Income stood at -$12.5 million in 2021, then plummeted by 62.13% to -$20.3 million in 2022, then tumbled by 44.38% to -$29.3 million in 2023, then plummeted by 57.89% to -$46.2 million in 2024, then crashed by 256.28% to -$164.7 million in 2025.
  • Its last three reported values are -$164.7 million in Q4 2025, -$98.6 million for Q3 2025, and -$74.6 million during Q2 2025.